Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
38,346,880
-
Number of holders
-
46
-
Total 13F shares, excl. options
-
25,847,504
-
Shares change
-
+502,994
-
Total reported value, excl. options
-
$242,550,140
-
Value change
-
+$2,249,753
-
Number of buys
-
20
-
Number of sells
-
-16
-
Price
-
$9.39
Significant Holders of Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA) as of Q1 2022
51 filings reported holding TRDA - Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q1 2022.
Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA) has 46 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 25,847,504 shares
of 38,346,880 outstanding shares and own 67% of the company stock.
Largest 10 shareholders include BAKER BROS. ADVISORS LP (4,704,419 shares), MPM ASSET MANAGEMENT LLC (4,425,784 shares), 5AM Venture Management, LLC (4,408,379 shares), WELLINGTON MANAGEMENT GROUP LLP (2,543,102 shares), PRICE T ROWE ASSOCIATES INC /MD/ (2,494,714 shares), Redmile Group, LLC (1,954,419 shares), FMR LLC (876,794 shares), StepStone Group LP (761,277 shares), TCG Crossover Management, LLC (663,694 shares), and 72 Investment Holdings, LLC (509,023 shares).
This table shows the top 46 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.